Evidence map›Paper›PMID 30579630›Full record

ReviewProgress in biophysics and molecular biology2019

Engineering hiPSC cardiomyocyte in vitro model systems for functional and structural assessment.

Alison Schroer, Gaspard Pardon, Erica Castillo, Cheavar Blair, Beth Pruitt

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Progress in biophysics and molecular biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Review
  2. Article
  3. Understanding hypertrophic cardiomyopathy and its regulation by myosin drugs.Protein science : a publication of the Protein Society · 2025
    Article
  4. Review
  5. Roles of funny HCN.Comparative biochemistry and physiology. Toxicology & pharmacology : CBP · 2025
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Hypertrophic cardiomyopathy β-cardiac myosin mutation (P710R) leads to hypercontractility by disrupting super relaxed state.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  14. Microphysiological systems: What it takes for community adoption.Experimental biology and medicine (Maywood, N.J.) · 2021
    Review
  15. Review
  16. Article
  17. MulticellularFrontiers in cardiovascular medicine · 2020
    Review
  18. Considerations for anFrontiers in pharmacology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alison SchroerDepartments of Mechanical Engineering and Bioengineering, Stanford University, Stanford, CA, 94305, USA. Electronic address: alisonschroer@gmail.com.
Gaspard PardonDepartments of Mechanical Engineering and Bioengineering, Stanford University, Stanford, CA, 94305, USA.
Erica CastilloDepartments of Mechanical Engineering and Bioengineering, Stanford University, Stanford, CA, 94305, USA; Department of Mechanical Engineering, University of California at Santa Barbara, USA.
Cheavar BlairDepartments of Mechanical Engineering and Bioengineering, Stanford University, Stanford, CA, 94305, USA; Department of Mechanical Engineering, University of California at Santa Barbara, USA.
Beth PruittDepartments of Mechanical Engineering and Bioengineering, Stanford University, Stanford, CA, 94305, USA; Department of Mechanical Engineering, University of California at Santa Barbara, USA.

Funding

Training in Myocardial Biology at Stanford (TIMBS)T32HL094274 · NHLBI · STANFORD UNIVERSITY · PI Euan A Ashley, Daniel Bernstein · 2010 to 2026
$5.0M
Validating engineered hiPSC-derived cardiomyocytes as model cellsR21HL130993 · NHLBI · UNIVERSITY OF CALIFORNIA SANTA BARBARA · PI PRUITT, BETH L · 2016 to 2017
$434k
Modeling myosin mechanobiology towards understanding the mechanisms of hypertrophic cardiomyopathyK99HL153679 · NHLBI · STANFORD UNIVERSITY · PI VANDER ROEST, ALISON SCHROER · 2021 to 2022
$329k
NHLBI NIH HHS K99 HL153679NHLBI NIH HHS R21 HL130993NHLBI NIH HHS T32 HL094274
6 · The paper itself

Abstract

The study of human cardiomyopathies and the development and testing of new therapies has long been limited by the availability of appropriate in vitro model systems. Cardiomyocytes are highly specialized cells whose internal structure and contractile function are sensitive to the local microenvironment and the combination of mechanical and biochemical cues they receive. The complementary technologies of human induced pluripotent stem cell (hiPSC) derived cardiomyocytes (CMs) and microphysiological systems (MPS) allow for precise control of the genetics and microenvironment of human cells in in vitro contexts. These combined systems also enable quantitative measurement of mechanical function and intracellular organization. This review describes relevant factors in the myocardium microenvironment that affect CM structure and mechanical function and demonstrates the application of several engineered microphysiological systems for studying development, disease, and drug discovery.

Indexed as

Cell EngineeringAnimalsCellular MicroenvironmentHumansInduced Pluripotent Stem CellsMyocytes, CardiacCardiac mechanobiologyDrug discoveryHeart-on-a-chipHuman induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs)In vitro cardiac modelMicrophysiological systems (MPS)

Identifiers

PMID30579630
PMCPMC6919215

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.